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Edited by Beat ImhofAbstract The chemokine MCP-1 is thought to play a key role –
among many other pathophysiological processes – in myocardial
infarction. MCP-1 is not only a key attractant for monocytes
and macrophages and as such responsible for inﬂammation but
might also be directly involved in the modulation of repair pro-
cesses in the heart. We show that cultured human cardiac cells
express MCP-1 and that its expression is upregulated by inﬂam-
matory cytokines and downregulated by hypoxia. We hypothe-
size that inﬂammation but not hypoxia is the main trigger for
monocyte recruitment in the human heart.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The chemokine monocyte chemoattractant protein 1 (MCP-
1) plays a key role in a variety of pathophysiological processes
in cardiovascular biology. As a key attractant for mononuclear
cells it is involved in the development and progression of car-
diovascular diseases such as atherosclerosis, restenosis and
thrombosis [1,2]. Several clinical studies report MCP-1 upreg-
ulation in patients with congestive heart failure [3] and dilated
cardiomyopathy [4]. Damas et al. [5] showed an increase in
MCP-1 in failing human hearts. Upregulation of MCP-1 in
the heart was also found in animal models of myocardial
infarction and reperfusion injury [6–8]. Furthermore a recent
report showed that blocking of MCP-1 reduces severity of
experimental autoimmune myocarditis in mice [9]. However,
besides detrimental eﬀects brought about by the inﬂammatory
capacity of monocytes and macrophages, MCP-1 seems to be
also involved in cardiovascular repair and protection. Inﬁltrat-
ing mononuclear cells appear to orchestrate cardiac repair pro-
cesses through a complex cascade involving cytokines and
growth factors [10]. A recent report shows that macrophage
inﬂammatory protein 2 (MIP-2) dependent MCP-1 expression
protects cardiac myocytes from cell death [11] and can also*Corresponding author. Fax: +43 1 40400 4216.
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[12]. By drilling tunnels through myocardial tissue monocytes
and macrophages were also reported to increase angiogenesis
in the heart [13]. MCP-1 is not only chemotactic for monocytes
but also for endothelial cells and thus can induce endothelial
cell sprouting and the chemokine seems to play a major role
in the growth of collateral vessels in ischemic tissue through
the recruitment of monocytes [14,15]. In MCP-1 null mice sup-
pression of macrophage recruitment as well as a decreased
inﬁltration with myoﬁbroblasts leads to a decreased number
of mature vessels with a muscular coat in the infarct zone of
the heart [16]. A recent report shows that MCP-1 can directly
act on endothelial cells and induce angiogenesis through induc-
tion of vascular endothelial growth factor (VEGF) [17].
Given the aforementioned evidence MCP-1 expression might
contribute to the development of heart failure but might also
be an important part of the repair process. It was the aim of
the present study to determine if human cardiac cells express
MCP-1 and if inﬂammation and hypoxia, two key factors in
cardiac damage and response to injury, aﬀect MCP-1 expres-
sion in human cardiac cells.2. Materials and methods
2.1. Isolation and cultivation of human adult cardiac cells
Human adult cardiac myocytes (HACM) and human adult cardiac
ﬁbroblasts (HACF) were isolated as previously described [18,19].
HACM stained positive for troponin I, tropomyosin, cardiotin and
myocardial muscle actin, HACF stained positive for ﬁbroblast speciﬁc
antigen. Cells were maintained in cell culture ﬂasks coated with 1% gel-
atin (Sigma, USA) in M199 (Sigma) containing 20% fetal calf serum
(Biochrom, Germany), 100 U/ml penicillin, 100 U/ml streptomycin,
0.25 lg/ml fungizone and 2 mM L-glutamine (all Cambrex, USA) at
37 C in a humidiﬁed atmosphere of 5% CO2:95% air.
All human material was obtained and processed according to the
recommendations of the hospital’s Ethics Committee including in-
formed consent.
2.2. Stimulation of HACM and HACF
Twenty-four hour prior to the experiments cells were starved with
M199 containing 0.1% BSA (Sigma). For stimulation experiments
with cytokines human recombinant tumor necrosis factor-a (TNF-
a), human recombinant interleukin-1a (IL-1a) (both Roche, Switzer-
land), IL-6 (Biosource, Germany), IL-10 and human recombinantblished by Elsevier B.V. All rights reserved.
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added in the given concentrations. For hypoxia cells were placed
in a Lab Chamber (PlasLabs, USA) and oxygen content was re-
duced below 1%. Oxygen concentration was permanently monitored
(Greisinger Electronic, Germany).
2.3. Antigen determination
MCP-1 antigen in conditioned media was determined by a speciﬁc
enzyme-linked immunosorbent assay (ELISA) as described in the man-
ufacturer’s instruction (Bender Med System, Austria). VEGF antigen
in conditioned media was determined by ELISA according to the man-
ufacturer’s instruction (R&D Systems).
2.4. Polymerase chain reaction
Real-Time-PCR (RT-PCR) was performed using LightCycler-RNA
Master SYBR Green I (Roche) according to the manufacturer’s
instructions. Primers were designed using Primer3 Software (http://
frodo.wi.mit.edu/), GAPDH-forward primer: 5 0-acagtccatgccatcactg-
cc-3 0, GAPDH-reverse primer: 5 0-gcctgcttcaccaccttcttg -3 0, beta-actin-
forward primer: 5 0-gtggcatccacgaaactacc-30, beta-actin-reverse primer:
5 0-cagggcagtgatctccttct-3 0, MCP-1-forward primer: 5 0-actgaagctcgtact-
ctc-3 0, MCP-1-reverse primer: 5 0-cttgggttgtggagtgag-30, CCR2-forward
primer: 5 0-agaggcatagggcagtgaga-3 0, CCR2-reverse primer: 50-gcagtgag-
tcatcccaagag-3 0. The ampliﬁcation conditions consisted of an initial
incubation at 61 C for 20 min, followed by incubation at 95 C for
30 s, 50 cycles of 95 C for 1 s, the respective annealing temperature
for 10 s and 72 C for 10 s, a melting step from 45 C to 95 C increas-
ing 0.1 C per second and a ﬁnal cooling to 40 C. Data were analyzed
using LightCycler Software Version 3.5 (Roche). RNA was isolated
using High Pure RNA Isolation Kit (Roche).
2.5. Immunohistochemical determination of MCP-1
Paraﬃn embedded pieces of healthy myocardium from donor hearts
unsuitable for transplantation and myocardium from patients suﬀering
from myocarditis were subjected to immunohistochemical staining for
MCP-1 using a commercially available anti-MCP-1 monoclonal mouse
antibody (R&D Systems) as described previously [18]. The antibody
was used at a concentration of 25 lg/ml. As secondary antibody an
ALEXA donkey anti-mouse antibody (Molecular Probes, USA)
was used at a concentration of 20 lg/ml. Nuclei were stained using
4 0,6-diamidino-2-phenylindole (DAPI)-Reagent (Merck, Germany) at
a concentration of 1 lg/ml.
2.6. Statistical analysis
Data were compared statistically by ANOVA. Values of P < 0.05
were considered signiﬁcant.3. Results
As can be seen from Table 1 unstimulated HACM as well as
HACF isolated from ﬁve diﬀerent donors, respectively, pro-
duced MCP-1. When such HACM and HACF were treated
with TNF-a (2000 U/ml) and IL-1a (200 U/ml) for 24 h toTable 1
Eﬀect of IL-1a and TNF-a on MCP-1 production in human adult cardiac my
from ﬁve diﬀerent donors
Donor #1 Donor #2 Donor #3
HACM HACF HACM HACF HACM
Control 54.6 ± 2.4 26.5 ± 3.2 38.5 ± 2.7 19.3 ± 2.3 20.4 ± 2.3
IL-1a 169.2 ± 3.2* 70.6 ± 2.4* 62.3 ± 5.0** 51.6 ± 4.8* 40.3 ± 5.5
TNF-a 180.2 ± 4.6* 80.5 ± 4.6* 64.5 ± 3.9** 55.8 ± 9.7* 47.8 ± 5.5
Conﬂuent monolayers of HACM and HACF, isolated from ﬁve diﬀerent dono
cardiomyopathy, donor 5: healthy donor heart, unsuitable for transplanta
(2000 U/ml) or IL-1a (200 U/ml). n.d.: not determined.
*P < 0.005.
**P < 0.05.simulate inﬂammatory conditions a signiﬁcant increase in the
production of MCP-1 protein was observed. However, other
pro- and anti-inﬂammatory mediators involved in the patho-
physiology of cardiovascular disease such as IL-6 (100 ng/
ml), IL-10 (100 ng/ml) and TGF-b (50 ng/ml) did not aﬀect
MCP-1 production in these cells (data not shown).
Incubation of HACM and HACF with increasing concen-
trations of TNF-a (2–2000 U/ml) or IL-1a (0.2–200 U/ml) re-
sulted in a dose dependent increase in MCP-1 protein
production (Fig. 1). MCP-1 was biologically active as it stim-
ulated migration of the monocytic cell line U937 in a Boyden
Chamber migration assay (data not shown).
To test if hypoxic conditions change the expression of MCP-
1, cells were cultured for 24 h with oxygen concentrations be-
low 1% with or without TNF-a (2000 U/ml) or IL-1a
(200 U/ml), respectively. Results are shown in Fig. 2. Hypoxia
signiﬁcantly down regulated MCP-1 basal expression levels.
Compared to the hypoxic control TNF-a and IL-1a increased
MCP-1 secretion under hypoxia to a similar extent as seen un-
der normoxic conditions, however total MCP-1 levels were sig-
niﬁcantly reduced compared to levels observed in cells treated
with these mediators under normoxic conditions. To evaluate
the ability of our cardiac cells to respond to hypoxia, VEGF,
whose production is known to be increased in cardiac cells un-
der hypoxia [20,21], was determined under normoxia and hy-
poxia. In contrast to MCP-1 VEGF was elevated up to
fourfold under hypoxic conditions in HACM and HACF com-
pared to normoxia (data not shown).
To test if hypoxia inducible factor 1a (HIF-1a) is involved in
the down regulation of MCP-1 we used CoCl2 (Sigma) to sta-
bilize HIF-1a under normoxic conditions as described [22,23].
CoCl2 dose-dependently reduced the basal secretion of MCP-1
in HACM and HACF (Fig. 3A and B). When cells were trea-
ted with 200 lM CoCl2 and TNF-a (2000 U/ml) or IL-1a
(200 U/ml) protein secretion was reduced compared to cells
treated with TNF-a or IL-1a alone (Fig. 3C and D).
As can be seen in Fig. 4 the results obtained at the protein
level were also reﬂected on the level of speciﬁc mRNA expres-
sion. TNF-a and IL-1a increased mRNA levels for MCP-1
after 8 h. Under hypoxic conditions the respective increases
were reduced. We used the housekeeping genes GAPDH and
beta-actin as controls. As the results of the two housekeeping
genes gave similar results only the values normalized for
GAPDH are shown.
When we investigated a possible regulation of the MCP-1
receptor CCR2 in our experiments using RT-PCR and speciﬁc
primers, we found a 2.3-fold upregulation of CCR2 speciﬁcocytes (HACM) and human adult cardiac ﬁbroblasts (HACF) isolated
Donor #4 Donor #5
HACM HACF HACM HACF
46.6 ± 2.3 n.d. 31.7 ± 4.0 31.3 ± 4.3 28.4 ± 4.3
* 107.0 ± 5.5* n.d. 39.4 ± 2.4** 56.0 ± 6.9** 93.7 ± 6.9*
* 131.5 ± 5.6* n.d. 60.0 ± 0.6* 71.0 ± 3.8* 90.2 ± 3.8*
rs (donors 1–4 explanted hearts from patients suﬀering from ischaemic
tion), were incubated for 24 h in the absence or presence of TNF-a
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Fig. 1. (A–D) Dose dependent eﬀect of TNF-a and IL-1a on MCP-1 production in human adult cardiac myocytes (HACM) and human adult
cardiac ﬁbroblasts (HACF). Conﬂuent monolayers of HACM (panels A and C) or HACF (panels B and D) were incubated for 24 h in the absence or
presence of TNF-a (A and B) or IL-1a (C and D). Values represent mean values ± S.D. of three independent determinations. Experiments were
performed three times with cells isolated from three diﬀerent donors. A representative experiment is shown. Data were compared by ANOVA. Values
of P < 0.05 were considered signiﬁcant. ***P < 0.00005, **P < 0.005, *P < 0.05.
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Fig. 2. Eﬀect of hypoxia and inﬂammatory cytokines on MCP-1 production in human adult cardiac myocytes (HACM) and human adult cardiac
ﬁbroblasts (HACF). Conﬂuent monolayers of HACM (panel A) or HACF (panel B) were incubated for 24 h under normoxic (open bars) or hypoxic
(grey bars) conditions in the presence or absence of IL-1a (200 U/ml) or TNF-a (2000 U/ml), respectively. Values represent mean values ± S.D. of
three independent determinations. Experiments were performed three times with cells isolated from three diﬀerent donors. A representative
experiment is shown. Data were compared by ANOVA. Values of P < 0.05 were considered signiﬁcant. For (A) ***P < 0.00005, **P < 0.0005 as
compared to normoxic control; /P < 0.05 as compared to normoxic control; #P < 0.00005 as compared to hypoxic control. For (B) ***P < 0.0005,
**P < 0.05 as compared to normoxic control; /P < 0.05 as compared to normoxic control; #P < 0.05 as compared to hypoxic control.
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Fig. 3. Eﬀect of CoCl2 on human adult cardiac myocytes (HACM) and human adult cardiac ﬁbroblasts (HACF). Conﬂuent monolayers of HACM
(panels A and C) or HACF (panels B and D) were incubated for 24 h with or without the indicated concentrations of CoCl2 (panels A and B) or with
TNF-a (2000 U/ml) or IL-1a (200 U/ml) in the absence or presence of 200 lMCoCl2 (panels C and D). Values represent mean values ± S.D. of three
independent determinations. Experiments were performed three times with cells isolated from three diﬀerent donors. A representative experiment is
shown. Data were compared by ANOVA. Values of P < 0.05 were considered signiﬁcant. ***P < 0.0005; **P < 0.005; *P < 0.05 as compared to
control; /P < 0.0005 as compared TNF-a or IL-1a alone, respectively.
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1a (200 U/ml) and hypoxia resulted only in a 1.2-fold and 1.4-
fold increase, respectively, after 8 h (Table 2). No evidence for
a regulation of CCR2 expression under these conditions was
seen in HACM.
When healthy myocardial tissue and myocardial tissue from
a patient suﬀering from acute myocarditis were subjected to
immunohistochemistry analysis for MCP-1 a more intense
staining for this protein was evident in the diseased heart
(Fig. 5).4. Discussion
Chemokines play an active role after myocardial infarction
through direct eﬀects on cardiac cells and through recruit-
ment of mononuclear cells [10]. In this setting recruited
monocytes and macrophages, which are a major source of
cytokines and growth factors, have detrimental eﬀects by ini-tiating cardiac remodeling but on the other hand might also
be involved in early cardiac repair. Here we show for the
ﬁrst time that cultured adult human cardiac myocytes and
adult human cardiac ﬁbroblasts express MCP-1. In order
to mimic inﬂammatory conditions characteristic for cardiac
injury the cells were treated with TNF-a and IL-1a. Such
treatment signiﬁcantly increased the production of MCP-1
protein. Other pro- and anti-inﬂammatory modulators such
as IL-6, IL-10 and TGF-b, however, had no eﬀect on
MCP-1 production in these cells. Although also found in
activated rat cardiac cells [24], MCP-1 protein production
in cardiac disease so far was mainly attributed to blood ves-
sels and macrophages [10]. Here we provide evidence that
human cardiac myocytes and ﬁbroblasts could also act as
a source for this chemokine.
In addition to inﬂammatory conditions [24] upregulation
of MCP-1 in rat cardiac cells was also seen under hypoxia
[25]. We report here that, in contrast to rat cardiac cells, hy-
poxia signiﬁcantly downregulates MCP-1 basal expression
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Fig. 4. Eﬀect of hypoxia and inﬂammatory cytokines on MCP-1 mRNA expression in human adult cardiac myocytes (HACM) and human adult
cardiac ﬁbroblasts (HACF). Conﬂuent monolayers of HACM (panel A) or HACF (panel B) were incubated for 8 h under normoxic (open bars) or
hypoxic (grey bars) conditions as described in Section 2 in the presence or absence of IL-1a (200 U/ml) or TNF-a (2000 U/ml), respectively. RNA was
prepared and real-time-PCR with primers speciﬁc for MCP-1, GAPDH and b-actin was performed as described in Section 2. Normalization of MCP-
1 mRNA levels according to the respective GAPDH and b-actin mRNA levels gave similar results. The normalization according to the respective
GAPDH levels is depicted in the ﬁgure. Values are given as percent of control and represent mean values ± S.D. of three independent determinations.
Experiments were performed two times with HACM and HACF isolated from two diﬀerent donors, respectively. A representative experiment is
shown. Data were compared by ANOVA. Values of P < 0.05 were considered signiﬁcant. For (A) **P < 0.0005, *P < 0.005 as compared to normoxic
control; /P < 0.05 as compared to normoxic control; #P < 0.05 as compared to hypoxic control. For (B) *P < 0.0005 as compared to normoxic
control; /P < 0.05 as compared to normoxic control; #P < 0.005 as compared to hypoxic control.
Table 2
Eﬀect of TNF-a, IL-1a and hypoxia on CCR2 mRNA expression in
human adult cardiac ﬁbroblasts (HACF)
CCR2 mRNA
Control 100 ± 4
TNF-a (2000 U/ml) 230 ± 10*
IL-1a (200 U/ml) 118 ± 7
Hypoxia 141 ± 4**
Conﬂuent monolayers of HACF were incubated for 8 h in the presence
or absence of TNF-a (2000 U/ml) or IL-1a (200 U/ml) or under hyp-
oxic conditions as described in Section 2, respectively. RNA was pre-
pared and real-time-PCR with primers speciﬁc for CCR2 and GAPDH
was performed as described in Section 2. CCR2 mRNA levels were
normalized according to the respective GAPDH levels and are given as
percent of control, which was set as 100%. The values represent mean
values ± S.D. of three independent determinations. Experiments were
performed two times with HACF isolated from two diﬀerent donors,
respectively. A representative experiment is shown.
*P < 0.005.
**P < 0.05.
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trol TNF-a and IL-1a increased MCP-1 secretion under hy-
poxia to a similar extent as under normoxic conditions,
however total MCP-1 levels were signiﬁcantly reduced com-
pared to levels observed in cells treated with these mediators
under normoxic conditions. In contrast to MCP-1, VEGF,
in agreement with earlier observations [20], was elevated
up to fourfold under hypoxia in human cardiac cells. In
our study the expression of MCP-1 was also reduced when
cells were treated with CoCl2, a stabilizing agent for HIF-
1a, alone or with a combination of CoCl2 and TNF-a or
IL-1a. Therefore we assume that HIF-1a is involved in mod-
ulating the expression of the chemokine under hypoxia.
Thus we provide evidence that, in contrast to rat cardiac
cells, stabilization of HIF-1a downregulates not only basal
MCP-1, but reduces the eﬀect of inﬂammatory cytokines un-
der hypoxic conditions. Therefore we suggest that HIF-1a is
directly involved in modulating the expression of the chemo-
kine under hypoxia. It should be noted, however, that
downregulation of MCP-1 by hypoxia was also observed
in human and murine macrophages [26] and in human syno-
vial ﬁbroblasts [27]. Furthermore a decrease of MCP-1 pro-
duction in ovarian cancer cells with a decrease in monocyte
migration under hypoxic conditions has been described [28].
Interestingly we found a robust upregulation of the expres-
sion of CCR2, the receptor of MCP-1, in TNF-a stimulated
adult human cardiac ﬁbroblasts but not in adult human car-
diac myocytes. Potential pathophysiological consequences of
CCR2 expression on cardiac cells and of a possible autocrine
loop between this receptor and MCP-1 produced by cardiac
cells remain elusive at this point of time. However it should
be emphasized in that respect that Damas et al. [5] described
the presence of CCR2 in the myocardium of patients with
end stage heart failure. The authors speculate that the expres-
sion of this chemokine receptor in the human heart mayrepresent a previously unrecognized pathogenic element in
the development of heart failure [5].
In order to support our in vitro ﬁndings that inﬂammatory
mediators enhance the expression of MCP-1 in cardiac cells
we used immunohistochemistry on samples of human myocar-
dial tissue. We provide evidence that MCP-1 expression is in-
creased in the myocardium in the in vivo setting under
inﬂammatory conditions, namely in myocardial tissue ob-
tained from a patient suﬀering from myocarditis.
In conclusion we show evidence for the ﬁrst time that hu-
man cardiac cells express biologically active MCP-1 and that
its expression is upregulated by inﬂammatory mediators and
downregulated by hypoxia. We hypothesize that – if also
operative in vivo – inﬂammation is the key trigger for
MCP-1 upregulation in human cardiac cells whereas hypoxia
Fig. 5. Immunohistochemical staining of MCP-1 in a healthy myo-
cardial section (panel A) and in a section of myocardial tissue from a
patient suﬀering from myocarditis (panel B). MCP-1 was visualized as
described in the Methods section. As compared to the healthy
myocardium (panel A) more intense MCP-1 staining is visible
throughout the tissue obtained from the patient suﬀering from
myocarditis (panel B). Similar results were seen when samples of
myocardium from another healthy individual and two other patients
suﬀering from myocarditis were analyzed.
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inﬂammatory environment. Thus we speculate that MCP-1
induced recruitment of mononuclear cells through human
cardiac cells is mainly associated with inﬂammation but
not with hypoxia. In addition we show for the ﬁrst time that
in human cardiac cells the expression of the MCP-1 receptor
CCR2 is upregulated by the inﬂammatory mediator TNF-a.
Our ﬁndings support the notion that cardiac expression of
both, MCP-1 and its receptor, could play a role in an auto-crine or paracrine loop involved in the pathogenesis of heart
disease [5]. Recent evidence has implicated MCP-1 and
CCR2 present in the myocardium of patients suﬀering from
heart failure in the pathogenesis of this disease [5]. In a mur-
ine model MCP-1 has been shown to play a critical role in
the development of autoimmune myocarditis [9]. Recently
MCP-1 has been shown to attenuate adverse postinfarction
remodeling at the expense of a prolonged inﬂammatory re-
sponse and delayed replacement of injured cardiac myocytes
after myocardial infarction in mice [16]. In view of such a
potential role of MCP-1 in these pathophysiological pro-
cesses in the heart, this cytokine and its expression in the
heart seems to deserve consideration as a possible target
for therapeutic intervention. However, further studies, pref-
erably in large mammalian models, seem warranted.
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